Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  1,234 نتائج ل ""Infliximab""

فلترة النتائج

Subject : antibodies, monoclonal
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.

  • Authors : Alharbi O; Gastroenterology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia.; Hamed W

Subjects: Biological Products* ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/epidemiology

  • Source: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 May-Jun; Vol. 29 (3), pp. 164-170.Publisher: Medknow Publications Country of Publication: India NLM ID: 9516979 Publication Model: Print Cited Medium: Internet ISSN: 1998-4049

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering.

  • Authors : Legrand P; Université Paris Cité, Faculté de sciences pharmaceutiques et biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1267, 4, avenue de l'observatoire, 75270, Paris Cedex 06, France. .; Département Recherche Et Développement Pharmaceutique, Agence Générale Des Equipements Et Produits de Santé (AGEPS), Assistance Publique-Hôpitaux de Paris, (AP-HP), Paris, France. .

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/chemistry ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/chemistry; Infliximab

  • Source: Analytical and bioanalytical chemistry [Anal Bioanal Chem] 2023 Jan; Vol. 415 (1), pp. 179-192. Date of Electronic Publication: 2022 Nov 30.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134327 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.

  • Authors : Yoo HK; Celltrion Healthcare, 19, Academy-ro 51, Yeonsu-gu, Incheon, South Korea.; Byun HG

Subjects: Antibodies, Monoclonal* ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy; Humans

  • Source: BMC health services research [BMC Health Serv Res] 2022 Nov 04; Vol. 22 (1), pp. 1319. Date of Electronic Publication: 2022 Nov 04.Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.

  • Authors : Mazza S; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milan, Italy.; Piazza O Sed N

Subjects: Drug Substitution* ; Treatment Outcome*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacology

  • Source: Clinical and translational science [Clin Transl Sci] 2022 Jan; Vol. 15 (1), pp. 172-181. Date of Electronic Publication: 2021 Sep 15.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.

  • Authors : Chow V; Clinical Pharmacology, Amgen Inc., Thousand Oaks, California, USA.; Oh M

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacokinetics ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*pharmacokinetics ; Infliximab/Infliximab/Infliximab/*pharmacokinetics

  • Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Feb; Vol. 9 (2), pp. 246-255. Date of Electronic Publication: 2019 Oct 19.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.

  • Authors : Martínez-Feito A; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain. .; Immunology Unit, La Paz University Hospital, Madrid, Spain. .

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacokinetics ; Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*pharmacokinetics ; Inflammatory Bowel Diseases/Inflammatory Bowel Diseases/Inflammatory Bowel Diseases/*drug therapy

  • Source: Scientific reports [Sci Rep] 2020 Oct 13; Vol. 10 (1), pp. 17099. Date of Electronic Publication: 2020 Oct 13.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.

Subjects: Adalimumab/Adalimumab/Adalimumab/*administration & dosage ; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use

  • Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 May; Vol. 51 (9), pp. 852-860. Date of Electronic Publication: 2020 Mar 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

  • Authors : Layegh Z; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.; Ruwaard J

Subjects: Drug Substitution*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*administration & dosage

  • Source: International journal of rheumatic diseases [Int J Rheum Dis] 2019 May; Vol. 22 (5), pp. 869-873. Date of Electronic Publication: 2019 Feb 14.Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.

  • Authors : Claudepierre P; Department of Rheumatology, Henri Mondor Hospital, APHP, and Université Paris Est Créteil, Créteil, France.; Van den Bosch F

Subjects: Efficiency* ; Work Performance*/Work Performance*/Work Performance*/economics; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use

  • Source: International journal of rheumatic diseases [Int J Rheum Dis] 2019 Jun; Vol. 22 (6), pp. 995-1001. Date of Electronic Publication: 2019 Apr 15.Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Merkel cell carcinoma in a patient treated with infliximab: Beware of the subcutaneous nodule.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*adverse effects ; Carcinoma, Merkel Cell/Carcinoma, Merkel Cell/Carcinoma, Merkel Cell/*chemically induced ; Crohn Disease/Crohn Disease/Crohn Disease/*drug therapy

  • Source: The Australasian journal of dermatology [Australas J Dermatol] 2018 Nov; Vol. 59 (4), pp. e288-e290. Date of Electronic Publication: 2018 Apr 16.Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0135232 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  1,234 نتائج ل ""Infliximab""